April’s top stories: Toshiba’s Aquilion Lightning CT, Abbott to buy St Jude Medical for $25bn
FDA grants clearance to Toshiba's Aquilion Lightning CT system, Abbott has agreed to St Jude Medical for $25bn. Medicaldevice-network.com wraps up the key headlines from April.
The US Food and Drug Administration (FDA) granted clearance to Toshiba America Medical Systems' Aquilion Lightning CT system with a powerful 50kW generator.
Toshiba's Aquilion Lightning is a 16-detector row system for routine volumetric scanning.
It addresses the clinical needs of hospitals looking for a dependable, premium-component, entry-level computerised tomography (CT) system that maximises their equipment investment.
US-based pharmaceuticals and health care products firm Abbott signed a definitive agreement to acquire medical device company St Jude Medical for $25bn.
Under the agreement, St. Jude Medical shareholders will receive $85 per share of Abbott common stock with $46.75 in cash.
The acquisition is projected to add 21 cents next year and 29 cents in 2018 to Abbott's adjusted earnings per share.
Israel-based Stratasys will partner with US company Jacobs Institute (JI) to develop a new Center of Excellence (COE) to expand the usage of 3D printing for a range of medical applications.
Stratasys' 3D printing technology will be used by the new COE to develop and assess new medical devices using 3D printed prototypes and models, and promote clinical education and training activities for a variety of audiences.
The 3D printing technology is said to accelerate medical procedures conducted by doctors, researchers and medical device manufacturers, enabling a thorough test and offer personalised care for patients.
Netherlands-based pharma company Norgine expanded its agreement with Apharm over the distribution of Ziverel, a class-III medical device, in Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, Norway, Sweden, Switzerland and the UK.
Ziverel is used to maintain the integrity of the oesophageal mucosa to deter the irritation of the oesophagus caused by stomach acid among other causes.
Gastrooesophageal reflux is a commonly occurring disease across the world and disease burden is said to be increasing. It affects up to 20% of the Western population and is associated with a range of risk factors.
Hologic secured US Food and Drug Administration (FDA) clearance and has commercially launched the Affirm prone biopsy system.
The company is a developer, manufacturer and supplier of diagnostic and medical imaging systems relating to women's health.
It is claimed to be the first dedicated prone biopsy system to generate both 2D and 3D imaging-guided breast biopsies.
US-based medical technology company Halyard Health entered into an agreement to acquire privately owned medical device company, CORPAK MedSystems (Corpak) for $174m.
Corpak, privately held by Linden Capital Partners, is instrumental in innovating enteral access solutions to enhance patient outcomes, safety and comfort.
Headquartered in Illinois, US, Corpak accounted for a sale of approximately $54m last fiscal year.
US-based privately held health technology company Seventh Sense Biosystems commenced a registration trial for its TAP Touch Activated Phlebotomy device, which is a painless diagnostic blood collection platform.
The trial will involve 120 subjects across three hospitals in the Northeast US, and is expected to be completed this month.
Seventh Sense Biosystems CEO Howard Weisman said: "The start of our pivotal trial moves us closer to delivering this device to patients and physicians, ultimately enabling blood collection to be performed whenever and wherever it is needed, and by anyone.
Pfizer collaborated with IBM to develop remote monitoring solutions to enhance the care offered by clinicians to patients afflicted with Parkinson's disease.
The experiment is said to involve a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers.
It is aimed at promoting a better understanding of the course of the disease, it will also help to shape the course of treatment in accordance to the information gathered, subsequently accelerating the development of new therapeutic options.
Medical technology company Intuity Medical secured the US Food and Drug Administration (FDA) clearance for its POGO automatic blood glucose monitoring system.
The POGO system is claimed to be the first blood glucose meter and multi-test cartridge to offer automatic testing with lancing, blood collection and analysis in one easy step.
It addresses the need of patients to regularly monitor their blood glucose to aid the management of their diabetes.